Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.

Authors :: Pleyer L
Germing U
Sperr WR
Linkesch W
Burgstaller S
Stauder R
Girschikofsky M
Schreder M
Pfeilstocker M
Lang A
Sliwa T
Geissler D
Schlick K
Placher-Sorko G
Theiler G
Thaler J
Mitrovic M
Neureiter D
Valent P
Greil R
Source :: Leukemia research [Leuk Res] 2014 Apr; Vol. 38 (4), pp. 475-83. Date of Electronic Publication: 2014 Jan 18.
Publication Year :: 2014
Abstract: Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p=0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p=0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML.<br /> (Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Subjects :: Activities of Daily Living
Adult
Aged
Aged, 80 and over
Disease Progression
Female
Humans
Male
Matched-Pair Analysis
Middle Aged
Survival Analysis
Antimetabolites, Antineoplastic therapeutic use
Azacitidine therapeutic use
Leukemia, Myelomonocytic, Chronic drug therapy
Leukemia, Myelomonocytic, Chronic mortality

Full Text Access

Tools